Answers are grounded in this paper and cite their sources.
Objectives To identify clinical and patient-reported variables associated with adherence to TNF inhibitors (TNFi) in a large, prospective, observational cohort study of people with RA. Methods Participants with a diagnosis of RA classified according to 1987 ACR criteria commencing a TNFi were recruited to a multi-centre UK-based observational cohort study between 2009-2019. Clinical characteristics and outcome measures were recorded by recruiting sites, and patient-reported outcome measures were collected via patient questionnaires. Adherence was recorded using a self-reported measure of adherence at each follow-up time-point. All potential predictors were assessed for their univariable and adjusted associations with adherence to TNFi using logistic regression, reported as odds ratios (OR) with 95% CI. Analysis was adjusted for potential confounders. Results A maximum of 1,007 participants had data available for analysis at baseline. Adherence was 91.46% at three months, 87.01% at six months and 83.59% at 12 months. Age at recruitment was significantly associated with TNFi adherence at three, six and 12 months in both univariable and adjusted analyses. HAQ scores at baseline, three months and 12 months were associated with adherence to TNFi at 12 months in both univariable and adjusted analyses. Conclusion Adherence was associated with increasing age at recruitment at all follow-up time-points, and adherence at 12 months was associated with increased HAQ scores at pre-treatment, three months and 12 months. Some factors associated with adherence are potentially modifiable and addressing these factors at treatment initiation may be helpful in improving medication adherence.
No takes yet. Share an insight, caveat, or question.
Ling et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: